MiMedx Group, Inc. MiMedx Group is an integrated developer, manufacturer and marketer of patent protected biomaterial based products. The company is successfully emerging from a development focused start up phase into a fully integrated operating company with expertise to capitalize on its science and technology and its capacity to generate sales growth and profitability.
Quote | MiMedx Group Inc (OTCMKTS:MDXG)
Last: | $6.56 |
---|---|
Change Percent: | 7.54% |
Open: | $6.35 |
Close: | $6.56 |
High: | $6.72 |
Low: | $6.28 |
Volume: | 261,058 |
Last Trade Date Time: | 11/03/2020 04:55:30 pm |
News | MiMedx Group Inc (OTCMKTS:MDXG)
2024-04-25 10:00:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 3...
Message Board Posts | MiMedx Group Inc (OTCMKTS:MDXG)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $MDXG News Article - MIMEDX Comments on Recent Data Brief Published by Office of Inspec | whytestocks | investorshangout | 03/16/2023 3:25:51 PM |
whytestocks: $MDXG News Article - MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Di | whytestocks | investorshangout | 01/30/2023 1:24:41 PM |
whytestocks: $MDXG News Article - MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expect | whytestocks | investorshangout | 01/09/2023 1:54:44 PM |
whytestocks: $MDXG News Article - MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer | whytestocks | investorshangout | 01/03/2023 4:10:49 PM |
Some positive PRs starting to move the needle. | bleedpurple | investorshub | 06/15/2022 7:44:53 PM |
News, Short Squeeze, Breakout and More Instantly...
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 3...
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Doubl...
MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity ...